Dose intensity analysis of high-dose carboplatin in refractory ovarian carcinoma relative to age



Background. Cisplatin and carboplatin are essential to management of advanced-stage epithelial ovarian carcinoma. No published data exist regarding carboplatin dose intensity importance in ovarian cancer, nor are there data for the effect of age on the ability to deliver dose-intensive carboplatin.

Methods. Retrospective dose intensity analyses were performed for 93 patients with advanced-stage refractory ovarian carcinoma, who received single-agent, high-dose carboplatin chemotherapy (800 mg/m2/35 days or 160 mg/m2/week). These patients had been treated on one of three high-dose carboplatin studies conducted in the Medicine Branch of the National Cancer Institute during the 1980s. Eligibility criteria required age greater than or equal to 18 years, good end organ function, and good performance status.

Results. Patients 60 years of age or older comprised 33% of the cohort and patients 70 years of age or older comprised 8% of the cohort. Administered dose intensity of carboplatin did not differ among age groups. Patients of age ≤ 39 years received a dose intensity of 136 ± 28 mg/m2/week, those of age 40–59 years received 129 ± 33, those of age ≥ 60 years received 134 ± 24, and those of age ≥ 70 years received 129 ± 19. Further, the administered carboplatin dose intensity did not differ among clinical response groups. Dose intensity in complete responders was 138 ± 18 mg/m2/week; in partial responders, 121 ± 29; and in nonresponders, 134 ± 30. The age distribution of responders matched the age distribution of the cohort.

Conclusions. These data demonstrate that elderly patients with good end organ function and good performance status tolerate the same level of dose-intensive platinum therapy as younger patients. Age alone should not be a determinant for carboplatin dose modification in the treatment of ovarian carcinoma.